Arrowhead Pharmaceuticals(US:ARWR)2025-02-10 21:03Financial Performance - Arrowhead Pharmaceuticals reported Q1 fiscal 2025 revenue of $2.5 million, a decrease of 29.5% from $3.55 million in Q1 fiscal 2024[6] - Operating loss for Q1 fiscal 2025 was $161.4 million, compared to a loss of $136.5 million in the same period last year, reflecting an increase of 18.2%[6] - Net loss attributable to Arrowhead Pharmaceuticals for Q1 fiscal 2025 was $173.1 million, compared to a loss of $132.9 million in Q1 fiscal 2024[6] - Total cash resources decreased to $552.9 million as of December 31, 2024, down from $681 million at the end of the previous quarter[6] - Arrowhead's stockholders' equity decreased to $52.6 million from $185.4 million in the previous quarter[6] Partnerships and Agreements - The company signed a licensing agreement with Sarepta Therapeutics, receiving $825 million upfront, including $500 million in cash and $325 million in equity investment, with potential additional payments of up to $10 billion[3] - Arrowhead is currently funded into 2028, with multiple wholly owned candidates providing opportunities for additional partnerships[2] Drug Development and Clinical Trials - Arrowhead's investigational drug plozasiran demonstrated mean triglyceride reductions of up to 73% in the MUIR study and 86% in the SHASTA-2 study[4] - The FDA accepted the New Drug Application for plozasiran, with a PDUFA action date set for November 18, 2025[3] - The company initiated a Phase 1/2a clinical trial for ARO-INHBE, targeting obesity, which showed promising preclinical results[4]